ImmunGene
Latest round
- Series A
Last raised
- Nov 2013
Total raised
- $9M
Investors
- 1
About ImmunGene
ImmunGene Inc.Founded in 2007, ImmunGene Inc. specializes in biotechnology solutions, specifically in immunotherapy. The company's headquarters is located in Thousand Oaks, US. The CEO, Sanjay Khare, has a history in the biotech sector.The company specializes in a range of innovative products and services designed to address specific market needs within their industry. Their core offerings focus on advanced solutions that streamline operational efficiency and enhance user experiences. These products are tailored for a diverse clientele, including large enterprises and small to medium-sized businesses, aiming to optimize processes, reduce costs, and improve overall productivity. Key market segments served by the company include the technology, healthcare, and education sectors, with products designed to be utilized in both operational and consumer-facing applications.ImmunGene generates revenue through a multi-faceted transaction structure predominantly based on B2B partnerships and direct sales to consumers. Their revenue model includes subscription services that provide clients with ongoing access to their software solutions, ensuring continuous updates and support. Flagship products, characterized by their innovative features and high demand, contribute significantly to the overall revenue stream. Clients typically engage in contractual agreements that outline specific pricing tiers based on usage levels, ensuring flexibility and scalability. The company is also targeting expansions into new markets in Europe and Asia by 2025, focusing on increasing its footprint in those regions. With a commitment to innovation, ImmunGene is actively designing cutting-edge therapies that are expected to be launched in the coming years.
Who invested in ImmunGene
1 investor across 1 round
See all investors in ImmunGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 7, 2013
Amount
$9M
Investors
Questions about ImmunGene
Who invested in ImmunGene?
ImmunGene has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmunGene raised?
ImmunGene has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ImmunGene last raise money?
ImmunGene's most recent round on record is a Series A, in Nov 2013.
What does ImmunGene do?
ImmunGene is a pharmaceuticals company.
Where is ImmunGene headquartered?
ImmunGene is headquartered in Thousand Oaks, US.
Which VCs invest in companies like ImmunGene?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at ImmunGene's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like ImmunGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.